Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q4 FY26 results · Jan–Mar 2026
Gufic Biosciences reported revenue from operations of ₹251.82 crore (up 22.8% from Q4 FY25) and net profit of ₹21.90 crore (up 183.6% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 251.82 | 205.02 | +22.8% | 231.41 | +8.8% |
| Other income | (1.17) | 0.39 | Turned loss | 0.79 | Turned loss |
| Total income | 250.65 | 205.41 | +22.0% | 232.20 | +7.9% |
| Profit before tax | 28.95 | 10.52 | +175.1% | 17.72 | +63.4% |
| Net profit for the period | 21.90 | 7.72 | +183.6% | 12.42 | +76.2% |
| EPS, basic (₹) | 2.18 | 0.77 | +183.1% | 1.24 | +75.8% |
| Net margin (%) | 8.7 | 3.8 | 5.4 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 252.05 | 205.02 | +22.9% | 231.09 | +9.1% |
| Other income | (1.20) | 0.38 | Turned loss | 0.79 | Turned loss |
| Total income | 250.86 | 205.40 | +22.1% | 231.89 | +8.2% |
| Profit before tax | 27.63 | 10.78 | +156.3% | 21.05 | +31.3% |
| Net profit for the period | 20.57 | 7.97 | +158.0% | 15.56 | +32.2% |
| EPS, basic (₹) | 2.05 | 0.80 | +156.2% | 1.55 | +32.3% |
| Net margin (%) | 8.2 | 3.9 | 6.7 |
Consolidated
- Filed with BSE
- 29 May 2026, 22:45 IST
- Board meeting
- 29 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 May 2026, 22:45 IST
- Board meeting
- 29 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE